BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 27053500)

  • 21. Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults.
    Zou Z; Yuan HB; Yang B; Xu F; Chen XY; Liu GJ; Shi XY
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD009210. PubMed ID: 26816003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide.
    Mamdani M; Gomes T; Greaves S; Manji S; Juurlink DN; Tadrous M; Kennedy SH; Antoniou T
    JAMA Netw Open; 2019 Oct; 2(10):e1913304. PubMed ID: 31617924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study.
    Yahyavi A; Hemmati N; Derakhshan P; Banivaheb B; Karimi Behnagh A; Tofighi R; TehraniYazdi A; Kabir A
    Intern Emerg Med; 2021 Jun; 16(4):883-893. PubMed ID: 33085063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: meta-analysis.
    Biswas M; Kali MSK
    Sci Rep; 2021 Mar; 11(1):5012. PubMed ID: 33658619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on in-hospital mortality among patients with COVID-19: a systematic review and meta-analysis.
    Cai XJ; Tay JCK; Kui SL; Tin AS; Tan VH
    Singapore Med J; 2021 Nov; 62(11):563-567. PubMed ID: 33256355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of the 'Better Care Better Value' prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design.
    Baker A; Chen LC; Elliott RA; Godman B
    BMC Health Serv Res; 2015 Sep; 15():367. PubMed ID: 26359265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use.
    Shin J; Kim H; Yim HW; Kim JH; Lee S; Kim HS
    J Clin Pharm Ther; 2022 Jan; 47(1):97-103. PubMed ID: 34668200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A retrospective cohort analysis of the effects of renin-angiotensin system inhibitors on spinal fusion in ACDF patients.
    Perdomo-Pantoja A; Shamoun F; Holmes C; Ishida W; Ramhmdani S; Cottrill E; Bydon A; Lo SL; Theodore N; Witham TF
    Spine J; 2019 Aug; 19(8):1354-1361. PubMed ID: 31059820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with abdominal aortic aneurysms: nation-wide cohort study.
    Kristensen KE; Torp-Pedersen C; Gislason GH; Egfjord M; Rasmussen HB; Hansen PR
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):733-40. PubMed ID: 25633315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study.
    Liu X; Liu Y; Chen K; Yan S; Bai X; Li J; Liu D
    J Med Virol; 2021 Feb; 93(2):854-862. PubMed ID: 32687223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.
    Xie Q; Tang S; Li Y
    Ann Palliat Med; 2022 Apr; 11(4):1253-1263. PubMed ID: 34775774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
    Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
    JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Morris ZS; Saha S; Magnuson WJ; Morris BA; Borkenhagen JF; Ching A; Hirose G; McMurry V; Francis DM; Harari PM; Chappell R; Tsuji S; Ritter MA
    Cancer; 2016 Aug; 122(16):2487-95. PubMed ID: 27203227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia.
    Georges JL; Gilles F; Cochet H; Bertrand A; De Tournemire M; Monguillon V; Pasqualini M; Prevot A; Roger G; Saba J; Soltani J; Koukabi-Fradelizi M; Beressi JP; Laureana C; Prost JF; Livarek B
    PLoS One; 2020; 15(12):e0244349. PubMed ID: 33347477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CT visual quantitative evaluation of hypertensive patients with coronavirus disease (COVID-19): Potential influence of angiotensin converting enzyme inhibitors / angiotensin receptor blockers on severity of lung involvement.
    Samanci C; Saylan B; Gulsen G; Akkaya Y; Yesildal M; Akkaya Isik S; Ustabasioglu FE
    Clin Exp Hypertens; 2021 May; 43(4):341-348. PubMed ID: 33583283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renin-angiotensin-aldosterone blockade reduces atrial fibrillation in hypertrophic cardiomyopathy.
    Huang CY; Yang YH; Lin LY; Tsai CT; Hwang JJ; Chen PC; Lin JL
    Heart; 2018 Aug; 104(15):1276-1283. PubMed ID: 29371376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines.
    Alcocer LA; Bryce A; De Padua Brasil D; Lara J; Cortes JM; Quesada D; Rodriguez P
    Am J Cardiovasc Drugs; 2023 Nov; 23(6):663-682. PubMed ID: 37668854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies.
    Kunutsor SK; Blom AW; Whitehouse MR; Kehoe PG; Laukkanen JA
    Eur J Epidemiol; 2017 Nov; 32(11):947-959. PubMed ID: 28752198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: A 15-year cohort study.
    Wu HY; Peng CL; Chen PC; Chiang CK; Chang CJ; Huang JW; Peng YS; Tu YK; Chu TS; Hung KY; Chien KL
    PLoS One; 2017; 12(5):e0177654. PubMed ID: 28505194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
    Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
    Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.